NASDAQ:HLVX HilleVax (HLVX) Stock Price, News & Analysis → get a piece of the profit from this land (From True Market Insiders) (Ad) Free HLVX Stock Alerts $15.84 +0.27 (+1.73%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$15.50▼$16.0550-Day Range$11.86▼$18.1252-Week Range$9.94▼$20.22Volume112,735 shsAverage Volume164,519 shsMarket Capitalization$787.56 millionP/E RatioN/ADividend YieldN/APrice Target$29.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get HilleVax alerts: Email Address HilleVax MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside83.1% Upside$29.00 Price TargetShort InterestHealthy3.29% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.07Based on 11 Articles This WeekInsider TradingSelling Shares$986.03 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.16) to ($3.05) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.21 out of 5 starsMedical Sector329th out of 919 stocksBiological Products, Except Diagnostic Industry47th out of 149 stocks 3.5 Analyst's Opinion Consensus RatingHilleVax has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageHilleVax has only been the subject of 2 research reports in the past 90 days.Read more about HilleVax's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.29% of the float of HilleVax has been sold short.Short Interest Ratio / Days to CoverHilleVax has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in HilleVax has recently increased by 16.11%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldHilleVax does not currently pay a dividend.Dividend GrowthHilleVax does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HLVX. Previous Next 1.7 News and Social Media Coverage News SentimentHilleVax has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for HilleVax this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for HLVX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, HilleVax insiders have sold 659,228.72% more of their company's stock than they have bought. Specifically, they have bought $149,550.00 in company stock and sold $986,026,106.00 in company stock.Percentage Held by Insiders29.30% of the stock of HilleVax is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.42% of the stock of HilleVax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about HilleVax's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for HilleVax are expected to grow in the coming year, from ($3.16) to ($3.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of HilleVax is -4.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of HilleVax is -4.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHilleVax has a P/B Ratio of 3.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about HilleVax's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.Click here for the full story… About HilleVax Stock (NASDAQ:HLVX)HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.Read More HLVX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HLVX Stock News HeadlinesMay 4, 2024 | insidertrades.comHilleVax, Inc. (NASDAQ:HLVX) Director Sells $10,230.45 in StockMay 17 at 2:10 AM | americanbankingnews.comQ2 2024 EPS Estimates for HilleVax, Inc. (NASDAQ:HLVX) Raised by Leerink PartnrsMay 16 at 1:38 AM | americanbankingnews.comHilleVax (NASDAQ:HLVX) Stock Price Up 6.1% Following Analyst UpgradeMay 14, 2024 | americanbankingnews.comHilleVax (NASDAQ:HLVX) Given "Buy" Rating at HC WainwrightMay 12, 2024 | americanbankingnews.comAnalyzing Ikena Oncology (NASDAQ:IKNA) & HilleVax (NASDAQ:HLVX)May 10, 2024 | msn.comHilleVax GAAP EPS of -$0.97 misses by $0.12May 10, 2024 | finance.yahoo.comHilleVax Inc (HLVX) Reports Increased Q1 Losses, Misses Analyst Earnings ExpectationsMay 10, 2024 | investorplace.comHLVX Stock Earnings: HilleVax Misses EPS for Q1 2024May 9, 2024 | finance.yahoo.comHilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company ProgressApril 7, 2024 | investing.comHillevax director Aditya Kohli sells shares worth over $264kMarch 22, 2024 | seekingalpha.comHilleVax: Mid-2024 Data Is Crucial Inflection Point For Continued ValuationMarch 21, 2024 | markets.businessinsider.comHilleVax, Inc’s HIL-214 Vaccine Candidate Promises Broad Protection Against Norovirus, Justifying Buy RatingMarch 20, 2024 | benzinga.comRecap: HilleVax Q4 EarningsMarch 20, 2024 | finance.yahoo.comHilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company ProgressMarch 20, 2024 | globenewswire.comHilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company ProgressFebruary 26, 2024 | msn.comJanux stock soars 96% in after hours trading on updated drug dataFebruary 23, 2024 | finance.yahoo.comDirector Aditya Kohli Sells 18,000 Shares of HilleVax Inc (HLVX)February 13, 2024 | benzinga.comAditya Kohli's Net WorthFebruary 5, 2024 | finance.yahoo.comHilleVax to Present at Guggenheim 6th Annual Biotechnology ConferenceJanuary 18, 2024 | markets.businessinsider.comHilleVax Appoints GSK's Sean McLoughlin As COOJanuary 18, 2024 | finance.yahoo.comHilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating OfficerJanuary 8, 2024 | finance.yahoo.comHilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of ChinaJanuary 5, 2024 | benzinga.comHilleVax Stock (NASDAQ:HLVX) Dividends: History, Yield and DatesJanuary 3, 2024 | finance.yahoo.comHilleVax to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 19, 2023 | finance.yahoo.comInsider Sell Alert: Chief Medical Officer Astrid Borkowski Sells 10,000 Shares of HilleVax Inc ...See More Headlines Receive HLVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HilleVax and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/20/2024Today5/18/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:HLVX CUSIPN/A CIK1888012 Webwww.hillevax.com Phone617-213-5054FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$29.00 High Stock Price Target$34.00 Low Stock Price Target$24.00 Potential Upside/Downside+83.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-123,570,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-56.18% Return on Assets-43.75% Debt Debt-to-Equity Ratio0.11 Current Ratio10.92 Quick Ratio10.62 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.80 per share Price / Book3.30Miscellaneous Outstanding Shares49,720,000Free Float35,153,000Market Cap$787.56 million OptionableNot Optionable Beta0.79 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Robert M. Hershberg M.D. (Age 62)Ph.D., President, CEO & Chairman of the Board Comp: $1.04MMr. Ozzie BergerSenior Vice President of Regulatory AffairsKey CompetitorsKyverna TherapeuticsNASDAQ:KYTXExscientiaNASDAQ:EXAIiTeos TherapeuticsNASDAQ:ITOSAdaptive BiotechnologiesNASDAQ:ADPTValnevaNASDAQ:VALNView All CompetitorsInsiders & InstitutionsTidal Investments LLCBought 12,465 shares on 5/17/2024Ownership: 0.025%California State Teachers Retirement SystemSold 1,510 shares on 5/16/2024Ownership: 0.040%EntryPoint Capital LLCBought 4,802 shares on 5/14/2024Ownership: 0.010%Vanguard Group Inc.Sold 102,168 shares on 5/10/2024Ownership: 2.741%SG Americas Securities LLCSold 1,065 shares on 5/7/2024Ownership: 0.015%View All Insider TransactionsView All Institutional Transactions HLVX Stock Analysis - Frequently Asked Questions Should I buy or sell HilleVax stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HilleVax in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HLVX shares. View HLVX analyst ratings or view top-rated stocks. What is HilleVax's stock price target for 2024? 4 Wall Street analysts have issued 12 month price targets for HilleVax's stock. Their HLVX share price targets range from $24.00 to $34.00. On average, they predict the company's stock price to reach $29.00 in the next year. This suggests a possible upside of 83.1% from the stock's current price. View analysts price targets for HLVX or view top-rated stocks among Wall Street analysts. How have HLVX shares performed in 2024? HilleVax's stock was trading at $16.05 on January 1st, 2024. Since then, HLVX stock has decreased by 1.3% and is now trading at $15.84. View the best growth stocks for 2024 here. When is HilleVax's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our HLVX earnings forecast. How were HilleVax's earnings last quarter? HilleVax, Inc. (NASDAQ:HLVX) posted its earnings results on Wednesday, March, 20th. The company reported ($0.78) earnings per share for the quarter, beating the consensus estimate of ($0.80) by $0.02. What ETFs hold HilleVax's stock? ETFs with the largest weight of HilleVax (NASDAQ:HLVX) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM).Morningstar US Small Growth (MSGR). When did HilleVax IPO? HilleVax (HLVX) raised $200 million in an IPO on Friday, April 29th 2022. The company issued 11,765,000 shares at a price of $16.00-$18.00 per share. Who are HilleVax's major shareholders? HilleVax's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.74%), California State Teachers Retirement System (0.04%), Tidal Investments LLC (0.03%), SG Americas Securities LLC (0.02%) and EntryPoint Capital LLC (0.01%). Insiders that own company stock include Aditya Kohli, Astrid Borkowski, Life Sciences X LP Frazier, Robert Hershberg, Sean Mcloughlin and Shane Maltbie. View institutional ownership trends. How do I buy shares of HilleVax? Shares of HLVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HLVX) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceNext President (Not Trump. Not Biden.)The Freeport SocietyWhat’s Really Next for America…Porter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersProtect Your Bank Account Before It’s Too LateWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HilleVax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
